1-2 a new section to read as follows:

1-3 1. No policy of health insurance that provides coverage for a drug

1-4 approved by the Food and Drug Administration for use in the treatment

1-5 of an illness, disease or other medical condition may be delivered or

1-6 issued for delivery in this state unless the policy includes coverage for

1-7 any other use of the drug for the treatment of cancer, if that use is:

1-8 (a) Specified in the most recent edition of or supplement to:

1-9 (1) The United States Pharmacopoeia Drug Information; or

1-10 (2) The American Hospital Formulary Service Drug Information;

1-11 or

1-12 (b) Supported by at least two articles reporting the results of scientific

1-13 studies that are published in scientific or medical journals, as defined in

1-14 21 C.F.R. § 99.3.

2-15 person residing in another state, and if the insurance commissioner or

2-16 corresponding public officer of that other state has informed the

2-17 commissioner that the policy is not subject to approval or disapproval by

2-18 that officer, the commissioner may by ruling require that the policy meet

2-19 the standards set forth in NRS 689A.030 to 689A.320, inclusive [.] , and

2-22 new section to read as follows:

2-23 1. No group policy of health insurance that provides coverage for a

2-24 drug approved by the Food and Drug Administration for use in the

2-25 treatment of an illness, disease or other medical condition may be

2-26 delivered or issued for delivery in this state unless the policy includes

2-27 coverage for any other use of the drug for the treatment of cancer, if that

2-28 use is:

2-29 (a) Specified in the most recent edition of or supplement to:

2-30 (1) The United States Pharmacopoeia Drug Information; or

2-31 (2) The American Hospital Formulary Service Drug Information;

2-32 or

2-33 (b) Supported by at least two articles reporting the results of scientific

2-34 studies that are published in scientific or medical journals, as defined in

2-35 21 C.F.R. § 99.3.

2-36 2. The coverage required pursuant to this section:

2-37 (a) Includes coverage for any medical services necessary to administer

2-38 the drug to the employee or member of the insured group.

2-39 (b) Does not include coverage for any:

2-40 (1) Experimental drug used for the treatment of cancer, if that drug

2-41 has not been approved by the Food and Drug Administration; or

2-42 (2) Use of a drug that is contraindicated by the Food and Drug

3-7 new section to read as follows:

3-8 1. No contract for hospital or medical services that provides coverage

3-9 for a drug approved by the Food and Drug Administration for use in the

3-10 treatment of an illness, disease or other medical condition may be

3-11 delivered or issued for delivery in this state unless the contract includes

3-12 coverage for any other use of the drug for the treatment of cancer, if that

3-13 use is:

3-14 (a) Specified in the most recent edition of or supplement to:

3-15 (1) The United States Pharmacopoeia Drug Information; or

3-16 (2) The American Hospital Formulary Service Drug Information;

3-17 or

3-18 (b) Supported by at least two articles reporting the results of scientific

3-19 studies that are published in scientific or medical journals, as defined in

3-20 21 C.F.R. § 99.3.

3-21 2. The coverage required pursuant to this section:

3-22 (a) Includes coverage for any medical services necessary to administer

3-23 the drug to a person covered under the contract.

3-24 (b) Does not include coverage for any:

3-25 (1) Experimental drug used for the treatment of cancer, if that drug

3-26 has not been approved by the Food and Drug Administration; or

3-27 (2) Use of a drug that is contraindicated by the Food and Drug

3-28 Administration.

3-29 3. A contract for hospital or medical services subject to the

3-30 provisions of this chapter that is delivered, issued for delivery or renewed

3-31 on or after October 1, 1999, has the legal effect of including the coverage

3-32 required by this section, and any provision of the contract that conflicts

3-35 new section to read as follows:

3-36 1. No evidence of coverage that provides coverage for a drug

3-37 approved by the Food and Drug Administration for use in the treatment

3-38 of an illness, disease or other medical condition may be delivered or

3-39 issued for delivery in this state unless the evidence of coverage includes

3-40 coverage for any other use of the drug for the treatment of cancer, if that

3-41 use is:

3-42 (a) Specified in the most recent edition of or supplement to:

4-21 certificate of authority issued to a health maintenance organization pursuant

4-22 to the provisions of this chapter if he finds that any of the following

4-23 conditions exist:

4-24 (a) The health maintenance organization is operating significantly in

4-25 contravention of its basic organizational document, its health care plan or in

4-26 a manner contrary to that described in and reasonably inferred from any

4-27 other information submitted pursuant to NRS 695C.060, 695C.070 and

4-28 695C.140, unless any amendments to those submissions have been filed

4-29 with and approved by the commissioner;

4-30 (b) The health maintenance organization issues evidence of coverage or

4-31 uses a schedule of charges for health care services which do not comply

4-32 with the requirements of NRS 695C.170 to 695C.200, inclusive, and

4-33 section 5 of this act, or 695C.207;

4-34 (c) The health care plan does not furnish comprehensive health care

4-35 services as provided for in NRS 695C.060;

4-36 (d) The state board of health certifies to the commissioner that [:

4-37 (1) The] the health maintenance organization [does] :

4-38 (1) Does not meet the requirements of subsection 2 of NRS

4-39 695C.080; or

4-40 (2) [The health maintenance organization is] Is unable to fulfill its

4-41 obligations to furnish health care services as required under its health care